⌘K
| Date | TitleTitle | |||
|---|---|---|---|---|
| 07/09/21 | 09:30:08 | 7 Sept 2021 | HUTCHMED to Present Clinical Data at ESMO | |
| 06/09/21 | 07:00:08 | 6 Sept 2021 | HUTCHMED Shares Included in Stock Connect Programs | |
| 02/09/21 | 12:45:06 | 2 Sept 2021 | Grant of Share Options, and Awards under LTIP | |
| 31/08/21 | 09:30:01 | 31 Aug 2021 | Total Voting Rights | |
| 26/08/21 | 07:00:03 | 26 Aug 2021 | Phase Ib/II Trial of Fruquintinib & Tislelizumab | |
| 23/08/21 | 07:00:06 | 23 Aug 2021 | HUTCHMED Selected for Certain Hang Seng Indexes | |
| 17/08/21 | 09:30:03 | 17 Aug 2021 | ELECTRONIC COMMUNICATION OF CORPORATE INFORMATION |
| Date | TitleTitle | |||
|---|---|---|---|---|
| 07/09/21 | 09:30:08 | 7 Sept 2021 | HUTCHMED to Present Clinical Data at ESMO | |
| 06/09/21 | 07:00:08 | 6 Sept 2021 | HUTCHMED Shares Included in Stock Connect Programs | |
| 02/09/21 | 12:45:06 | 2 Sept 2021 | Grant of Share Options, and Awards under LTIP | |
| 31/08/21 | 09:30:01 | 31 Aug 2021 | Total Voting Rights | |
| 26/08/21 | 07:00:03 | 26 Aug 2021 | Phase Ib/II Trial of Fruquintinib & Tislelizumab | |
| 23/08/21 | 07:00:06 | 23 Aug 2021 | HUTCHMED Selected for Certain Hang Seng Indexes | |
| 17/08/21 | 09:30:03 | 17 Aug 2021 | ELECTRONIC COMMUNICATION OF CORPORATE INFORMATION |